Ramiro G. Peru, a director at Elevance Health, Inc. (NYSE:ELV), recently purchased $366,050 worth of the company’s common stock. The transaction, which occurred on July 17, 2026, involved the acquisition of 1,000 shares at a price of $366.05 per share. The purchase comes as the stock has declined 10.4% over the past week, though InvestingPro analysis suggests the company remains undervalued at current levels.
Following this purchase, Mr. Peru directly owns 10,908 shares of Elevance Health common stock. According to InvestingPro Tips, management has been aggressively buying back shares—one of 10+ additional insights available to subscribers.
In other recent news, Elevance Health reported stronger-than-expected second-quarter 2026 results, with adjusted earnings of $7.45 per share, surpassing Wall Street’s forecast of $6.21. The company’s revenue also exceeded expectations, reaching $49.8 billion compared to the anticipated $48.63 billion. Elevance Health has raised its full-year earnings and cash-flow outlook, despite concerns over margin pressure in its Medicaid segment. As part of its Medicaid strategy, Elevance announced plans to exit the Washington, D.C. market and potentially other markets over the next 12 to 18 months.
Analyst firms have responded to these developments with varied perspectives. RBC Capital lowered its price target for Elevance to $424, maintaining a Sector Perform rating, while Bernstein reiterated an Outperform rating with a $482 price target. On a more positive note, Guggenheim increased its price target to $455, citing strong operational performance and benefits from the restructured Medicare Advantage product. These updates come amid a broader sector recovery, highlighted by UnitedHealth Group’s improved 2026 guidance, which positively influenced Elevance’s stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News
